{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:45:24Z","timestamp":1792079124931,"version":"4.4.0"},"reference-count":8,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:p>This Viewpoint discusses recent US Food and Drug Administration (FDA) decisions regarding oncology drug trials for refractory melanoma and their potential negative impacts on the US regulatory environment.<\/jats:p>","DOI":"10.1001\/jamaoncol.2026.2843","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:00:44Z","timestamp":1787238044000},"page":"1063","source":"Crossref","is-referenced-by-count":0,"title":["Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US"],"prefix":"10.1001","volume":"12","author":[{"given":"Gilberto","family":"Lopes","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center at the University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"cvp260011r6","author":"McKelvey","year":"2026"},{"key":"cvp260011r1","unstructured":"US Food and Drug Administration. Frequently asked questions: breakthrough therapies. March 21, 2024. Accessed June 4, 2026. https:\/\/www.fda.gov\/regulatory-information\/food-and-drug-administration-safety-and-innovation-act-fdasia\/frequently-asked-questions-breakthrough-therapies"},{"key":"cvp260011r2","unstructured":"Editorial Board. Dr. Makary and Mr. Hyde at the FDA. Wall Street Journal. April 14, 2026. Accessed July 24, 2026. https:\/\/www.wsj.com\/opinion\/replimune-melanoma-rp1-fda-vinay-prasad-marty-makary-a45fa5bf"},{"key":"cvp260011r3","unstructured":"Editorial Board. Oncologists vs the FDA and RFK Jr. Wall Street Journal. April 21, 2026. Accessed July 24, 2026. https:\/\/www.wsj.com\/opinion\/fda-rp1-replimune-melanoma-drug-rfk-jr-vinay-prasad-marty-makary-b8d666b2"},{"key":"cvp260011r4","unstructured":"Editorial Board. RFK Jr. confronts the FDA on a cancer drug. Wall Street Journal. April 23, 2026. Accessed July 24, 2026. https:\/\/www.wsj.com\/opinion\/rfk-jr-replimune-melanoma-drug-catherine-cortez-masto-marty-makary-9d53f47e"},{"key":"cvp260011r5","unstructured":"IQVIA Institute for Human Data Science. Global oncology trends 2025: adopting new therapies as modalities shift and expenditures rise. May 22, 2025. Accessed July 22, 2026. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2025"},{"key":"cvp260011r7","unstructured":"US Food and Drug Administration. Complete response letter: BLA 125827, vusolimogene oderparepvec. April 10, 2026. Accessed July 24, 2026. https:\/\/download.open.fda.gov\/crl\/CRL_BLA125827_20260410.pdf"},{"key":"cvp260011r8","unstructured":"National Cancer Institute. NCI Community Oncology Research Program (NCORP). Accessed June 4, 2026. https:\/\/www.cancer.gov\/research\/infrastructure\/clinical-trials\/ncorp"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2853214\/jamaoncology_lopes_2026_vp_260011_1792007344.48708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:48Z","timestamp":1792076448000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2853214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.2843","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}